BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 35813625)

  • 1. Associations of Uric Acid With Liver Steatosis and Fibrosis Applying Vibration Controlled Transient Elastography in the United States: A Nationwide Cross-Section Study.
    Duan H; Zhang R; Chen X; Yu G; Song C; Jiang Y; He Y; Wan H; Shen J
    Front Endocrinol (Lausanne); 2022; 13():930224. PubMed ID: 35813625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Marijuana use is inversely associated with liver steatosis detected by transient elastography in the general United States population in NHANES 2017-2018: A cross-sectional study.
    Du R; Tang XY; Yang C; Gao WH; Gao SJ; Xiang HJ; Yang L
    PLoS One; 2023; 18(5):e0284859. PubMed ID: 37200309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood pressure, glycemic status and advanced liver fibrosis assessed by transient elastography in the general United States population.
    Ciardullo S; Monti T; Grassi G; Mancia G; Perseghin G
    J Hypertens; 2021 Aug; 39(8):1621-1627. PubMed ID: 33657584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver fibrosis assessed by transient elastography is independently associated with albuminuria in the general United States population.
    Ciardullo S; Ballabeni C; Trevisan R; Perseghin G
    Dig Liver Dis; 2021 Jul; 53(7):866-872. PubMed ID: 33685807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with significant liver steatosis and fibrosis as assessed by transient elastography in patients with one or more components of the metabolic syndrome.
    Mikolasevic I; Milic S; Orlic L; Stimac D; Franjic N; Targher G
    J Diabetes Complications; 2016; 30(7):1347-53. PubMed ID: 27324703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease.
    Siddiqui MS; Vuppalanchi R; Van Natta ML; Hallinan E; Kowdley KV; Abdelmalek M; Neuschwander-Tetri BA; Loomba R; Dasarathy S; Brandman D; Doo E; Tonascia JA; Kleiner DE; Chalasani N; Sanyal AJ;
    Clin Gastroenterol Hepatol; 2019 Jan; 17(1):156-163.e2. PubMed ID: 29705261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations between dietary flavonoid intake with hepatic steatosis and fibrosis quantified by VCTE: Evidence from NHANES and FNDDS.
    Xie R; Zhang Y
    Nutr Metab Cardiovasc Dis; 2023 Jun; 33(6):1179-1189. PubMed ID: 36964061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between hypertension and the prevalence of liver steatosis and fibrosis.
    Fu H; Yu H; Zhao Y; Chen J; Liu Z
    BMC Endocr Disord; 2023 Apr; 23(1):85. PubMed ID: 37081417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ALT poorly predicts Nonalcoholic Fatty Liver Disease (NAFLD) and liver fibrosis as determined by vibration-controlled transient elastography in adult National Health and Nutrition Examination Survey 2017-2018.
    Condon S; Hu H; Kong M; Cave MC; McClain CJ
    Am J Med Sci; 2024 May; 367(5):310-322. PubMed ID: 38307172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults: Results from NHANES 2017-2018.
    Zhang X; Heredia NI; Balakrishnan M; Thrift AP
    PLoS One; 2021; 16(6):e0252164. PubMed ID: 34081733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility of Fibroscan in Assessment of Hepatic Steatosis and Fibrosis in Obese Patients: Report From a General Internal Medicine Clinic.
    Avcu A; Kaya E; Yilmaz Y
    Turk J Gastroenterol; 2021 May; 32(5):466-472. PubMed ID: 34231477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between weight-adjusted-waist index with hepatic steatosis and liver fibrosis: a nationally representative cross-sectional study from NHANES 2017 to 2020.
    Shen Y; Wu Y; Fu M; Zhu K; Wang J
    Front Endocrinol (Lausanne); 2023; 14():1159055. PubMed ID: 37274346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of liver stiffness and controlled attenuation parameter measured by transient elastography with diabetes mellitus in patients with chronic liver disease.
    Ahn JM; Paik YH; Kim SH; Lee JH; Cho JY; Sohn W; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    J Korean Med Sci; 2014 Aug; 29(8):1113-9. PubMed ID: 25120322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes.
    Ciardullo S; Monti T; Perseghin G
    Diabetes Care; 2021 Feb; 44(2):519-525. PubMed ID: 33303638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NAFLD and Liver Fibrosis Are Not Associated With Reduced Femoral Bone Mineral Density in the General US Population.
    Ciardullo S; Muraca E; Zerbini F; Manzoni G; Perseghin G
    J Clin Endocrinol Metab; 2021 Jul; 106(8):e2856-e2865. PubMed ID: 33878156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic Fatty Liver Disease, Liver Fibrosis and Cardiovascular Disease in the Adult US Population.
    Ciardullo S; Cannistraci R; Mazzetti S; Mortara A; Perseghin G
    Front Endocrinol (Lausanne); 2021; 12():711484. PubMed ID: 34381424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes.
    Ciardullo S; Perseghin G
    Metabolism; 2021 Aug; 121():154752. PubMed ID: 33716004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic dysfunction-associated steatotic liver disease-related hepatic fibrosis increases risk of insulin resistance, type 2 diabetes, and chronic kidney disease.
    Zhang W; Song WJ; Chen W; Pan Z; Zhang J; Fan L; Li J
    Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):802-810. PubMed ID: 38526946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations of Serum Iron Status with MAFLD and Liver Fibrosis in the USA: a Nationwide Cross-Section Study.
    Yu G; Liu L; Qin T; Luo Y; Song C; Chen X; Duan H; Jiang Y; Zeng H; Wan H; Shen J
    Biol Trace Elem Res; 2024 Jan; 202(1):87-98. PubMed ID: 37079265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.